Dupilumab
Brand name: Dupixent Pen
Rank #29 of 500 drugs by total cost
$609.1M
Total Cost
156,267
Total Claims
$609.1M
Total Cost
6,392
Prescribers
$3,898
Cost per Claim
3,045
Beneficiaries
160,700
30-Day Fills
$95K
Avg Cost/Provider
24
Avg Claims/Provider
About Dupilumab
Dupilumab (sold as Dupixent Pen) was prescribed 156,267 times by 6,392 Medicare Part D providers in 2023, costing the program $609.1M. At $3,898 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 26 | Cyclosporine (Restasis) | $684.1M | 723,620 |
| 27 | Linaclotide (Linzess) | $639.4M | 823,023 |
| 28 | Insulin Lispro (Humalog Kwikpen U-100) | $623.9M | 854,813 |
| 29 | Dupilumab (Dupixent Pen) | $609.1M | 156,267 |
| 30 | Rsvpref3 Antigen/As01e/Pf (Arexvy) | $608.6M | 1,935,431 |
| 31 | Pomalidomide (Pomalyst) | $589.0M | 27,253 |
| 32 | Lipase/Protease/Amylase (Zenpep) | $577.7M | 321,809 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology